Diabetes mellitus (DM) affects 2-37% of patients with chronic obstructive pulmonary disease (COPD), with results being highly variable between studies. DM may also correlate with disease characteristics.The aim of this study was to examine the prevalence of DM and its correlation with comorbidities and COPD characteristics in patients with COPD admitted for exacerbation. 152 patients were studied for presence of DM. All of them were (13/44) of females (p=0.379). The prevalence of DM in this study is significantly higher when compared to an unselected Bulgarian population (12,8% in subjects over 45 years).
A total of 152 COPD patients hospitalized for exacerbation were studied for the presence of 69 DM, prediabetes, MS and vitamin D deficiency and insufficiency using well-established criteria for: The diagnosis of COPD was made according to GOLD (Global Initiative for Chronic 83 Obstructive Lung Disease) criteria (1) . Data were gathered for age, sex, smoking status and number of 84 pack-years, number of bone fractures, therapy for arterial hypertension, therapy for DM, COPD 85 therapy and number of exacerbations in the last year. The patients completed CAT and mMRC 86 questionnaires and underwent pre-and post bronchodilatatory spirometry. Blood pressure was obtained 87 according to the American Heart Association Guidelines (48). A patient was considered as having 88 arterial hypertension if taking antihypertensives. 89 The inclusion criteria were post bronchodilator spirometry obstruction defined as 90 FEV1/FVC<0.70. All participants in this study signed informed consent.
91
The exclusion criteria were failure to comply with study procedures (no completed 92 According to the available studies the prevalence of DM in COPD patients varies between 2-184 37% (table 2) . This study found relatively high prevalence of DM compared to previous studies ( fig.  185 1) . The prevalence of DM and prediabetes in our study is significantly higher when compared to the 186 general Bulgarian population (12,8% and 5,6% respectively in subjects over 45 years) (28). The odds 187 ratio for COPD patients admitted for exacerbation of having DM is 3.44 (95% CI 2.38-4.97), which is 188 higher than previous reported (table 3) . Prevalence of DM is high in Bulgaria (12,8%) and it is even 189 higher in COPD patients admitted for exacerbation (34,9%). The prevalence results could be explained with differences between the populations in different 211 studies (physical activity, diet, lifestyle etc.). For example, Bulgaria is low-income country, which may 212 impact diet preferences and treatment choices. Second, the prevalence depends on the used criteria for 213 DM (this study uses all of them, so it cannot be underdiagnosed). Not least, patients in this study had 214 been hospitalized due to exacerbation, which represents the most severe group of COPD patients.
215
The COPD patients admitted for exacerbation are a risk group for DM and a screening should 216 be considered. HbA1c have biggest sensitivity. According to another study smokers are 30-40% more likely to develop DM than nonsmokers 220 and the risk increases with the number of pack-years (53). Our study did not find significant 221 differences in prevalence of DM and prediabetes in neversmokers and eversmokers (former and 222 current). However the prevalence of current smokers was higher in patients without DM (34,3 vs. 223 11,3%) while the prevalence of former smokers was lower (48,5 vs. 75,5%, p=0.003). Number of pack-224 years did not differ significantly according to the presence of DM (p=0.626). These results could be 225 explained with smoke being the biggest factor in developing COPD and effect of developing DM could 226 be reduced. Also lifestyle changes (quit smoking) in the presence of the two diseases should be 227 considered.
228
Treatment with inhalatory corticosteroids (ICS) is not associated with higher prevalence of DM 229 and prediabetes (p=0.742 and p=0.283 respectively) confirming the results by other authors (54). 230 Glycemic control (HbA1c) in patients with DM in this study did not differ between the seasons 231 (p=0.196) as described by other authors (55), probably because of lower seasonal differences in 232 physical activity as a consequence of limited pulmonary function.
233
Most of the patients with DM in this study are former smokers. Glycemic control did not differ 234 between seasons.
236 Comorbidity results

237
COPD is a disease that affects mainly the lungs, but is characterized by systemic inflammation 238 and a number of extrapulmonary manifestations. Only 1/3 of patients with COPD die due to respiratory 239 failure. Main cause of death is lung cancer and cardiovascular complications (56).
240
The vast majority of patients with COPD have a vitamin D deficiency (57). Aside from its role 241 in the metabolism of calcium and phosphorus, vitamin D is involved in the pathogenesis of multiple 242 diseases, including DM, because it affects the secretion and the function of insulin (23). In our study 243 Hyperglycemia is associated with elevated glucose concentrations in tissues and bronchial 269 aspirates (58) where it may stimulate infection by enhancing bacterial growth (59) and by promoting 270 bacterial interaction with the airway epithelium (60). Hyperglycemia also impairs both innate and 271 adaptive immunity, suppressing the host response to infection.
272
The presence of DM increase the risk of exacerbations almost two fold (16), the risk of 273 hospitalization (3) and is associated with more serious deterioration which may prolong hospital stay 274 (17-21). However one study found no effect of DM on the frequency of exacerbations (61).
275
Our study found a significant difference between the number of severe exacerbations according 276 to the presence of DM and the duration of hospital stay (table 5, p=0.003 and p=0.006 respectively). 277 The risk for severe exacerbation and duration of hospital stay are furthermore increased in COPD 278 patients with untreated (new) DM (p=0.001 and p=0.026 respectively). Known (treated) DM is not 279 associated with increased number of moderate, severe and total exacerbations (all p>0.05) but prolongs 280 hospital stay (p=0.039). Prediabetes is not associated with increased risk of exacerbation and duration 281 of hospital stay (table 5, all p>0.05).
282
Triglycerides and blood glucose levels in our study did not correlate with number of 283 exacerbations as reported by other authors (62), nor did other MS components or MS itself (all 284 p>0.05). 286 
295
Our study did not find difference between mMRC and CAT scores in relation to the presence of 296 DM or prediabetes (table 6). Prevalence of DM is not significantly different between patients with less 297 symptoms (CAT 0-9) and breathlessness (mMRC 0 or 1) compared to patients with more symptoms 298 (CAT ≥10) and breathlessness (mMRC ≥2) (all p>0.05) (table 1). This is in contrast with the data about 299 reduced quality of life in patients with DM (9) but may be explained with COPD having higher 300 negative impact on quality of life than DM (physical limitation due to shortness of breath) (63) and 301 ameliorating the effect in patients having the two diseases. This study finds high prevalence of DM (34,9%) in COPD patients admitted for exacerbation. 333 DM is more prevalent in males, but the gender difference is not statistically significant. In this study 334 most of the patients are former smokers and glycemic control does not differ between seasons. 335 The presence of DM is associated with presence of MS, more severe exacerbations 336 (hospitalizations) during the previous year and longer hospital stay. DM is not associated with reduced 337 quality of life, but is a risk factor for FVC.
338
Patients with COPD admitted for exacerbation are at great risk for impaired glucose metabolism 339 which may impact natural course of COPD. 34,9% of them have DM and 30,9% have prediabetes. The 340 majority of the patients in this study are unaware of having DM and a screening should be considered.
